This article provides an explanation of how researchers estimate human pharmacokinetic parameters for electronic nicotine delivery systems (ENDS) by analyzing their aerosols. Understanding these parameters helps assess how effectively ENDS deliver nicotine compared to traditional cigarettes.
Such insights are crucial for evaluating the potential of ENDS as harm reduction tools and informing public health policies aimed at reducing tobacco-related health risks.